Although around 60% of NSCLC patients exhibit molecular alterations amenable to targeted therapy, such as mutations in EGFR, ALK, ROS1 and KRAS, the remaining patients, especially those with LUSC (lung squamous cell carcinoma), lack available targets, not to mention the drug resistance associated with current targeted therapies. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.